MedPage Today on MSN
FDA Calls for Testing Before Treatment With Widely Used Chemotherapies
Notice highlights risks of DPD deficiency with capecitabine, fluorouracil ...
The FDA updated its safety labeling for capecitabine and 5-FU to reflect that patients with certain genetic variants risk ...
Complete DPD deficiency markedly impairs 5-FU catabolism, increasing risk of early severe diarrhea, mucositis, neutropenia, ...
Before patients with cancer begin treatment with intravenous fluorouracil and related drugs, they should be tested for lack of the enzyme dihydropyrimidine dehydrogenase (DPD), says an EU panel.
The clinical description of severe toxicity fails to capture the suffering, shock, and tragedy experienced by our loved ones who were fatally overdosed after not being offered this important and ...
The labeling updates address the risk of early-onset toxicity, including life-threatening adverse events in patients with DPD ...
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...
Dr. Gabriel A. Brooks discusses what DPD deficiency is and why it is important for patients with cancer receiving 5-FU or Xeloda to be aware of it. The Food and Drug Administration (FDA) has updated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results